Press releases
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
Feb 25, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/322/neogenomics-launches-radar-st-expanding-molecular-residual-disease-testing-across-multiple-solid-tumor-types
NeoGenomics to Participate in Upcoming Investor Conferences
Feb 18, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/321/neogenomics-to-participate-in-upcoming-investor-conferences
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
Feb 17, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/320/neogenomics-reports-fourth-quarter-and-full-year-2025-results
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
Feb 12, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/319/neogenomics-introduces-pantracer-pro-to-support-timely-informed-solid-tumor-therapy-selection
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Jan 27, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/318/neogenomics-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-17-2026
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
Jan 12, 2026
https://ir.neogenomics.com/news-events/press-releases/detail/317/neogenomics-announces-preliminary-fourth-quarter-and-full-year-2025-revenue
CTA style
Default